Update on Cymbalta severe withdrawal symptoms trial: Fibromyalgia alert
A jury has cleared Eli Lilly in a trial about Cymbalta causing serious withdrawal symptoms. This was the first of four trials about the same issue with the antidepressant. An estimated group of 250 plaintiffs accused the company of downplaying the severe withdrawal symptoms caused by the drug. Cymbalta was originally designed to treat depression, but the Food and Drug Administration expanded its use as a treatment for fibromyalgia and generalized anxiety disorder.
There was no victory for Claudia Herrera, who was one of the plaintiffs suing Eli Lilly, in the trial in California. Reuters reports that the jury cleared the company, and Eli Lilly remains optimistic as it faces the other three trials. Claudia Herrera claimed that she suffered from severe withdrawal after trying to quit Cymbalta. Despite following her doctor’s orders to gradually reduce the doses, Herrera suffered from a variety of symptoms including spasms and suicidal thoughts. She accused the company of not emphasizing the withdrawal symptoms.
It is important to note that Cymbalta was originally marketed as an antidepressant and used to treat anxiety and depression. However, the Food and Drug Administration approved the use of the drug for other conditions including fibromyalgia. Cymbalta has also been used to treat chronic back pain, arthritis, nerve pain and other health problems. The most common side effects are nausea, drowsiness, fatigue, dizziness and sweating. However, the plaintiffs in the case against the company argue that the withdrawal symptoms are severe and not being acknowledged.
Patients report that Cymbalta withdrawal symptoms include suicidal thoughts, electrical shock sensations, anxiety, fatigue, insomnia, dizziness, nightmares and headaches. Other symptoms have also been reported, and the patients argue that the company has downplayed withdrawal from the medication. In addition, patients report that they still suffer from severe withdrawal despite following the guidelines to gradually decrease the dose.
Read more about fibromyalgia:
Memantine drug shows promise for fibromyalgia
Fibromyalgia study focuses on brain stimulation to fight pain